RPL27A

Large ribosomal subunit protein uL15 · P46776 · RPL27A on Sugi Atlas →

3,671 patent compounds predicted against RPL27A, 1,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL27A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer	PHASE1/PHASE2	COMPLETED
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Mitoquines in COPD	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPL27A binder may also engage these)

Protein	Name	Similarity
Q5REY2	—	0.998	Q5REY2 →
P18445	—	0.997	P18445 →
Q5R1X0	—	0.995	Q5R1X0 →
P14115	—	0.991	P14115 →
Q4R723	—	0.988	Q4R723 →
Q56K03	—	0.987	Q56K03 →
G1SNY0	—	0.982	G1SNY0 →
P62912	—	0.934	P62912 →
Q76KA3	—	0.934	Q76KA3 →
E2RKA8	—	0.934	E2RKA8 →
Q6QAT0	—	0.930	Q6QAT0 →
P62911	—	0.930	P62911 →
Q3SZQ6	—	0.929	Q3SZQ6 →
Q56JV1	—	0.928	Q56JV1 →
RPS26	Small ribosomal subunit protein eS26 (40S rib	0.926	landscape →
P61251	—	0.926	P61251 →
P62855	—	0.926	P62855 →
A5JSS2	—	0.925	A5JSS2 →
RPL32	Large ribosomal subunit protein eL32 (60S rib	0.924	landscape →
Q6QN05	—	0.924	Q6QN05 →
P49171	—	0.924	P49171 →
P20280	—	0.923	P20280 →
P49666	—	0.922	P49666 →
G1SHQ2	—	0.921	G1SHQ2 →
RPL21	Large ribosomal subunit protein eL21	0.920	landscape →
O09167	—	0.919	O09167 →
G1SQH0	—	0.915	G1SQH0 →
P61255	—	0.915	P61255 →
P30742	—	0.914	P30742 →
P61257	—	0.912	P61257 →